Patents by Inventor Ren Kong

Ren Kong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION
    Publication number: 20240043837
    Abstract: The present invention relates to nucleic acids, double stranded nucleic acids (dsNAs), and agents for inhibiting expression of STATS. The present invention also includes nanoparticles comprising the nucleic acids, the dsNAs, and/or the agents as well as methods of treating cancer using the nucleic acids, the double stranded nucleic acids (dsNAs), the agents and/or the nanoparticles as disclosed herein. In one embodiment, the target region is within the 3?-UTR region of STATS mRNA.
    Type: Application
    Filed: August 6, 2021
    Publication date: February 8, 2024
    Inventors: Boon Cher GOH, Li Ren KONG
  • NOVEL STAT3 INHIBITORS IDENTIFIED BY STRUCTURE-BASED VIRTUAL SCREENING INCORPORATING SH2 DOMAIN FLEXIBILITY
    Publication number: 20220168322
    Abstract: In one aspect, the present disclosure provides methods of inhibiting STAT3 in a cell comprising contacting the cell with a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure provides methods of using of the compounds disclosed herein for the treatment of cancer.
    Type: Application
    Filed: July 19, 2019
    Publication date: June 2, 2022
    Applicants: Board of Regents, The University of Texas System, The Methodist Hospital dba Houston Methodist Hospital
    Inventors: David John TWEARDY, Ren KONG, Uddalak BHARADWAJ, Moses Makokha KASEMBELI, Stephen T. C. WONG
  • Compositions and methods for selectively inhibiting intestinal carboxylesterase 2 enzyme activity
    Patent number: 10314811
    Abstract: A method for treating diarrhea induced by a chemotherapy agent by administering a carboxylesterase 2 (CES2) inhibitor, i.e., hesperetin, naringenin, or 2?,4?-dihydroxychalcone. Also disclosed is a method for treating cancer by administering a chemotherapy agent together with hesperetin, naringenin, or 2?,4?-dihydroxychalcone. Furthermore, a composition for treating cancer is provided, the composition containing a chemotherapy agent and hesperetin, naringenin, or 2?,4?-dihydroxychalcone.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: June 11, 2019
    Assignee: The Methodist Hospital
    Inventors: Ren Kong, Hong Zhao, Stephen T. C. Wong
  • COMPOSITIONS AND METHODS FOR SELECTIVELY INHIBITING INTESTINAL CARBOXYLESTERASE 2 ENZYME ACTIVITY
    Publication number: 20180235928
    Abstract: A method for treating diarrhea induced by a chemotherapy agent by administering a carboxylesterase 2 (CES2) inhibitor, i.e., hesperetin, naringenin, or 2?,4?-dihydroxychalcone. Also disclosed is a method for treating cancer by administering a chemotherapy agent together with hesperetin, naringenin, or 2?,4?-dihydroxychalcone. Furthermore, a composition for treating cancer is provided, the composition containing a chemotherapy agent and hesperetin, naringenin, or 2?,4?-dihydroxychalcone.
    Type: Application
    Filed: August 18, 2016
    Publication date: August 23, 2018
    Inventors: Ren Kong, Hong Zhao, Stephen T.C. Wong
  • 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
    Patent number: 8648086
    Abstract: The present invention provides 5,6-bicyclic heteroaryl-containing urea compounds of Formula I or II and use of the same for treating conditions mediated by protein kinase such as VEGFR2, c-Met, PDGFR? c-Kit, CSF1R, or EphA2.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: February 11, 2014
    Assignee: Ascepion Pharmaceuticals, Inc.
    Inventors: Shan Jiang, Xinglong Xing, Qishan Wang, Ren Kong
  • 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20120122895
    Abstract: The present invention provides 5,6-bicyclic heteroaryl-containing urea compounds of Formula I or II and use of the same for treating conditions mediated by protein kinase such as VEGFR2, c-Met, PDGFR? c-Kit, CSF1R, or EphA2.
    Type: Application
    Filed: August 20, 2010
    Publication date: May 17, 2012
    Inventors: Shan Jiang, Xinglong Xing, Qishan Wang, Ren Kong